Fennec Pharmaceuticals Delivers Record Net Product Sales of $44.6 Million in 2025
Fennec Pharmaceuticals has reported a record-breaking performance in its net product sales for the year 2025. According to the company's fourth quarter and full year 2025 earnings conference call, held on March 24, 2026, Fennec achieved $44.6 million in net product sales, surpassing the previous year's figure of $29.6 million.
The significant growth was driven by a quarter-over-quarter expansion in active patients as well as new and existing accounts. This achievement reinforces the durability and demand for the company's market development strategies, highlighting its effectiveness in addressing the needs of cancer patients.
During the fourth quarter, Fennec made strategic decisions to further enhance its execution and reach by increasing its customer-facing team and expanding its capabilities into new territories and high-prescribing targets. The company also strengthened its financial health through disciplined operating decisions and efficiency measures, including a successful public offering that raised over $42 million in net proceeds.
The full-service patient support program, Fennec HEARS, achieved record performance in the fourth quarter, reaching all-time highs in patient enrollments, prescribed and infused vials, active patients, and conversion rates. The program was designed to simplify access and support continuity of care by guiding patients through coverage, reimbursement, and providing free product for eligible individuals, as well as coordinating nurse-led administration and at-home infusion services.
The company's CEO, Jeff Hackman, emphasized that the growth in 2025 was driven by quarter-over-quarter expansion with active patients and new/existing accounts. He also highlighted the importance of the company's market development strategies in driving this growth and noted that the strengthened balance sheet positions Fennec well for long-term value creation.
The Chief Medical Officer, Dr. Pierre S. Sayad, joined the call to discuss the substantial progress being made on the medical front and the importance of the medical team in the education process of CIO and PEDMARK. His remarks underscored the company's commitment to advancing its medical strategy and clinical evidence.
Fennec Pharmaceuticals' record-breaking performance in 2025 underscores the company's success in delivering effective solutions for cancer patients, while also maintaining a strong financial foundation. As the company continues to scale, its focus on high-impact initiatives and efficiency measures positions it well for long-term value creation.
